Target Bets Big on Hemp THC as Congress Eyes Veterans' Cannabis Access

Editor's Brief

Friday, May 8, 2026 brings a full plate of cannabis news spanning retail, policy, and cultivation. Target's surprise expansion of hemp THC beverages into 300+ stores is raising eyebrows industry-wide, while Congress juggles veterans' medical cannabis access and bipartisan pressure on the FDA over psychedelic therapies.

On the legal frontier, North Carolina moves closer to putting cannabis questions directly to voters, and Pennsylvania inches toward a dedicated Cannabis Control Board. Meanwhile, a federal lawsuit targeting major MSOs over alleged false medical claims could reshape how the industry markets its products.

For growers and enthusiasts, today's most compelling reads touch on triploid "mutant" cannabis genetics and a California clone market that just hit jaw-dropping price points. Buckle up — it's a big news day.

Top Story

Target's Hemp THC Gamble: Calculated Move or Corporate Miscalculation?

Target is expanding intoxicating hemp-derived THC beverages into more than 300 stores across Florida, Texas, and Illinois — just six months before a potential federal ban could wipe the category off shelves entirely. The move is either a bold clearance play or a signal that Target's legal team knows something the rest of the industry doesn't.

Hemp-derived THC drinks have occupied a legal gray zone since the 2018 Farm Bill inadvertently opened the door to intoxicating cannabinoids. Federal regulators have been signaling a crackdown for months, yet here is one of America's largest retailers doubling down. The calculus may be simple: sell through inventory before any ban takes effect, pocket the margin, and exit cleanly.

But there's a more optimistic read. Target's legal and compliance teams are not known for reckless gambling. If they're expanding the category, they may have reason to believe federal enforcement timelines are softer than advertised — or that a carve-out for low-dose beverage products is quietly being discussed in regulatory corridors.

For consumers, this is a rare window to access hemp THC beverages at mainstream retail prices with the convenience of a big-box store. For the broader cannabis industry, it's a stress test — if Target normalizes hemp THC at scale and no federal hammer falls, it could permanently reshape the legal landscape for plant-touching operators who have spent years fighting for shelf space.

Policy & Legalization

Congress Takes Up Veterans' Cannabis Access

A medical cannabis amendment for veterans is once again circulating on Capitol Hill, paired with bipartisan pressure on the FDA to accelerate psychedelic therapy approvals. The veterans' amendment reflects growing mainstream consensus that cannabis should be available to those who served, regardless of federal scheduling status.

North Carolina Puts Cannabis to the Voters

A new North Carolina bill would place two separate constitutional amendments on November ballots — one for medical cannabis, one for adult use. Letting voters decide directly bypasses legislative gridlock and could make North Carolina the next major Southeast state to legalize. Watch this one closely through summer.

Racial Disparities Persist Despite Reform

New research from Cornell confirms that while cannabis legalization has significantly reduced overall arrest rates, racial disparities in enforcement remain stubbornly intact. The data is a sobering reminder that policy reform without equity-focused implementation leaves the most impacted communities behind.

Business & Markets

MSOs Face Federal Lawsuit Over Medical Claims

A class action filed in federal court targets Cresco Labs, Green Thumb, and a third major MSO over allegedly false medical claims made about their cannabis products. Filed on behalf of 42 customers across a dozen states, the lawsuit could have sweeping implications for how licensed operators market therapeutic benefits. This is a landmark legal test for the industry's marketing practices — and a warning shot for any brand making unsubstantiated health claims.

Pennsylvania Creates Cannabis Control Board

The Pennsylvania Senate Law & Justice Committee approved a bill establishing a dedicated Cannabis Control Board to oversee both the existing medical program and a future adult-use market. Institutional infrastructure signals serious intent — Pennsylvania's adult-use legalization may be closer than the headlines suggest.

Cannabis Stocks Remain Stagnant

New Cannabis Ventures reports that cannabis equities continue to tread water with no meaningful catalysts pushing share prices in either direction. Federal rescheduling delays, market saturation in mature states, and the looming MSO lawsuit are all headwinds. Investors watching this space should temper short-term expectations.

Science & Cultivation

'Mutant Marijuana': Triploid Cannabis Goes Mainstream Outdoors

Triploid cannabis — plants engineered with three sets of chromosomes instead of two — is gaining serious traction among outdoor cultivators. Because triploids are nearly always seedless, they eliminate the grower's biggest nightmare: accidental pollination ruining a crop of sensimilla. The results in real-world outdoor grows are promising, though not without complications around rooting, vigor, and yield consistency.

For home growers, triploid genetics represent a meaningful leap in crop security — especially for those cultivating in environments where male plants or hemp fields nearby pose a pollination risk. Expect to see more nurseries offering triploid cuts as demand accelerates through 2026.

California Clone Market Reaches Staggering Price Points

Three major California clone release events this May are moving elite cuttings — including Tire Fire OG, Tom Hill Haze, and Toad Venom — for up to $1,566 per cut. Purple City Genetics and Hendrx Nursery are among the headliners. The collector genetics market is now operating like fine art auctions, with provenance and exclusivity driving prices far beyond the average grower's budget.

Americans Microdose Cannabis More Than Any Other Substance

A UCSF study finds that cannabis microdosing is far more prevalent than psychedelic microdosing — occurring at nearly twice the rate of LSD or psilocybin use. Researchers suggest the conversation around microdosing has been dominated by psychedelics while quietly, millions of Americans are already using low-dose cannabis for focus, mood, and sleep. This has real implications for how cultivators and dispensaries think about low-THC product development.

Culture & Community

Harvard Doc's New Book: Cannabis as Senior Care Revolution

Dr. Peter Grinspoon's new book Aging Well with Cannabis is making waves as a Harvard-credentialed, evidence-based guide for seniors and caregivers navigating pharmaceutical overload. With older Americans representing one of the fastest-growing consumer segments in cannabis, this book arrives at exactly the right moment. It's the kind of mainstream legitimization the plant has needed for decades.

Mary Jane Berlin Turns 10

Mary Jane Berlin returns June 11–14 at Messe Berlin for its landmark 10th anniversary, drawing an expected 75,000+ attendees and 500+ international exhibitors. RAW founder Josh Kesselman headlines a live podcast on opening day. For anyone tracking the global cannabis scene, this is the event of the European summer.

What This Means for Growers

• Triploid genetics are worth exploring in 2026. If you grow outdoors near uncontrolled male plants or hemp operations, triploid cuts offer a meaningful layer of crop protection against accidental pollination.
• The clone collector market is pricing out hobbyists. With elite cuts hitting $1,500+, community clone swaps and trusted local breeders become more valuable than ever for home growers on a budget.
• Microdosing demand should inform your strain selection. Growing lower-THC, terpene-rich cultivars positions you well for personal use and gifting as microdosing culture expands.
• North Carolina's ballot push matters if you're in the Southeast. A successful vote this November would open legal home grow conversations in a region that has been locked down for years.
• Watch the MSO false-claims lawsuit carefully. If courts rule that cannabis companies can't make health claims without clinical backing, it reshapes the entire value proposition of buying from a dispensary versus growing your own medicine at home.

Quick Links

Full source links are listed below this article.